TMB-365 and TMB-380 in Suppressed HIV-1 Infected Individuals
- Conditions
- HIV-1-infection
- Interventions
- Drug: TMB-365/TMB-380
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- TaiMed Biologics Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT05275998
- Locations
- ๐บ๐ธ
Orlando Immunology Center, Orlando, Florida, United States
๐บ๐ธMidway Immunology and Research Center, Fort Pierce, Florida, United States
๐บ๐ธNorth Texas Infectious Disease Consultants, Dallas, Texas, United States
Dose Escalation Safety Study of TMB-365 in HIV-1 Infected Participants
- Conditions
- HIV-1-infection
- Interventions
- Biological: TMB-365
- First Posted Date
- 2019-07-22
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- TaiMed Biologics Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04027387
- Locations
- ๐บ๐ธ
Quest Clinical Research, San Francisco, California, United States
๐บ๐ธMidway Immunology and Research Center, Fort Pierce, Florida, United States
๐บ๐ธUniversity of Mississippi Medical Center Division of Infectious Diseases, Jackson, Mississippi, United States
Study of the Safety of Trogarzoโข Administered as an Undiluted "IV Push" or an Intramuscular Injection
- First Posted Date
- 2019-04-12
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- TaiMed Biologics Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT03913195
- Locations
- ๐บ๐ธ
Anthony Mills MD Inc., Los Angeles, California, United States
๐บ๐ธGary Richmond MD, PA, Fort Lauderdale, Florida, United States
๐บ๐ธNorth Texas Infectious Disease Consultants, Dallas, Texas, United States
Study of the Safety, Tolerability and Pharmacokinetics of TMB-607 in HIV-Negative Volunteers
- First Posted Date
- 2017-04-12
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- TaiMed Biologics Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT03110549
- Locations
- ๐บ๐ธ
Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, United States
Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1
- First Posted Date
- 2016-03-14
- Last Posted Date
- 2021-03-11
- Lead Sponsor
- TaiMed Biologics Inc.
- Target Recruit Count
- 79
- Registration Number
- NCT02707861
- Locations
- ๐บ๐ธ
Palmtree Clinical Research, Inc., Palm Springs, California, United States
๐บ๐ธSouthern California Permanente Medical Group, Los Angeles, California, United States
๐บ๐ธCharles R. Drew University of Medicine and Science, Clinical and Translational Research Center, Los Angeles, California, United States
Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV
- Conditions
- HIV
- Interventions
- Biological: ibalizumabDrug: Optimized Background Regimen (OBR)
- First Posted Date
- 2015-06-19
- Last Posted Date
- 2020-03-19
- Lead Sponsor
- TaiMed Biologics Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT02475629
- Locations
- ๐บ๐ธ
University of Maryland, Institute of Human Virology, Baltimore, Maryland, United States
๐บ๐ธResearch Access Network, Houston, Texas, United States
๐บ๐ธW King Health Care Group, Los Angeles, California, United States
Safety Study of Ibalizumab Subcutaneous Injection in Healthy Volunteers
- Conditions
- Prevention of Infection With HIV-1
- Interventions
- Biological: ibalizumab (biologic/MAb) for SC Injection or placebo
- First Posted Date
- 2011-02-09
- Last Posted Date
- 2012-12-18
- Lead Sponsor
- TaiMed Biologics Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT01292174
- Locations
- ๐บ๐ธ
Alabama Vaccine Research Center, Birmingham, Alabama, United States
๐บ๐ธQuest Clinical Research, San Francisco, California, United States
๐บ๐ธACRIA - AIDS Community Research Initiative of America, New York, New York, United States
Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1
- First Posted Date
- 2008-11-02
- Last Posted Date
- 2014-05-05
- Lead Sponsor
- TaiMed Biologics Inc.
- Target Recruit Count
- 113
- Registration Number
- NCT00784147
- Locations
- ๐บ๐ธ
Nationsmed Clinical Research, Houston, Texas, United States
๐บ๐ธDr. Gordon E. Crofoot, MD, PA, Houston, Texas, United States
๐บ๐ธUniversity of Miami, Miller School of Medicine, Miami, Florida, United States